Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 11
1999 14
2000 37
2001 62
2002 56
2003 65
2004 58
2005 102
2006 67
2007 64
2008 83
2009 77
2010 80
2011 60
2012 58
2013 45
2014 52
2015 38
2016 54
2017 52
2018 48
2019 41
2020 28
2021 19
Text availability
Article attribute
Article type
Publication date

Search Results

1,173 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean daclizumab (1,171 results)?
Daclizumab.
Mottershead M, Neuberger J. Mottershead M, et al. Expert Opin Biol Ther. 2007 Oct;7(10):1583-96. doi: 10.1517/14712598.7.10.1583. Expert Opin Biol Ther. 2007. PMID: 17916050 Review.
Daclizumab is a humanized monoclonal antibody which binds to the IL-2 receptor on activated lymphocytes and blocks the production of IL-2. ...The agent is generally well tolerated in adults and children and there is no need for additional monitoring. Daclizumab has
Daclizumab is a humanized monoclonal antibody which binds to the IL-2 receptor on activated lymphocytes and blocks the production of
Daclizumab for MS.
[No authors listed] [No authors listed] Drug Ther Bull. 2017 Feb;55(2):18-21. doi: 10.1136/dtb.2017.2.0454. Drug Ther Bull. 2017. PMID: 28183723 Review.
Daclizumab (Zinbryta-Biogen Idec) is a new injectable disease-modifying drug licensed for the treatment of relapsing forms of multiple sclerosis (MS) in adults.(1) It is a humanised monoclonal antibody that modulates interleukin-2 signalling.(1-3) Here, we review the evide
Daclizumab (Zinbryta-Biogen Idec) is a new injectable disease-modifying drug licensed for the treatment of relapsing forms of multipl
Daclizumab in multiple sclerosis.
Perez-Miralles FC. Perez-Miralles FC. Rev Neurol. 2018 Apr 16;66(8):271-282. Rev Neurol. 2018. PMID: 29645071 Free article. Review. English, Spanish.
INTRODUCTION: Daclizumab is a monoclonal antibody directed against the CD25 subunit of the interleukin-2 receptor, investigated as a disease-modifying therapy in relapsing-remitting multiple sclerosis. ...CONCLUSIONS: Daclizumab has shown efficacy in slowing the inf …
INTRODUCTION: Daclizumab is a monoclonal antibody directed against the CD25 subunit of the interleukin-2 receptor, investigated as a …
Daclizumab Therapy for Multiple Sclerosis.
Bielekova B. Bielekova B. Cold Spring Harb Perspect Med. 2019 May 1;9(5):a034470. doi: 10.1101/cshperspect.a034470. Cold Spring Harb Perspect Med. 2019. PMID: 29661806 Free PMC article. Review.
Daclizumab is a humanized monoclonal antibody that prevents formation of high-affinity interleukin (IL)-2 receptor (IL-2R). ...However, the mechanism of action (MOA) of daclizumab is surprisingly broad and it includes many unanticipated effects on innate immunity. .
Daclizumab is a humanized monoclonal antibody that prevents formation of high-affinity interleukin (IL)-2 receptor (IL-2R). ...Howeve
Advancements in the management of uveitis.
Schwartzman S. Schwartzman S. Best Pract Res Clin Rheumatol. 2016 Apr;30(2):304-315. doi: 10.1016/j.berh.2016.07.005. Epub 2016 Oct 31. Best Pract Res Clin Rheumatol. 2016. PMID: 27886802 Review.
Adalimumab has been recently approved for intermediate uveitis, posterior uveitis, and panuveitis. Other biologic agents have been tested, including daclizumab, a monoclonal antibody directed against IL-2, anti-IL1, and anti-IL-6 receptor agents and therapies that block an …
Adalimumab has been recently approved for intermediate uveitis, posterior uveitis, and panuveitis. Other biologic agents have been tested, i …
[Immunosuppression in kidney transplantation].
Balssa L, Bittard H, Kleinclauss F; Comité de transplantation de l'Association française d'urologie. Balssa L, et al. Prog Urol. 2011 Apr;21(4):250-3. doi: 10.1016/j.purol.2010.08.048. Epub 2010 Oct 20. Prog Urol. 2011. PMID: 21482398 Review. French.
Daclizumab for the treatment of multiple sclerosis.
Papadopoulou A, Derfuss T, Sprenger T. Papadopoulou A, et al. Neurodegener Dis Manag. 2017 Oct;7(5):279-297. doi: 10.2217/nmt-2017-0023. Epub 2017 Aug 29. Neurodegener Dis Manag. 2017. PMID: 28849702 Review.
Daclizumab is a monoclonal antibody that targets the alpha-chain of the IL-2 receptor. ...Certain aspects of the immunomodulatory mode of action of daclizumab were only discovered during its clinical development, such as the expansion of a subpopulation of natural k
Daclizumab is a monoclonal antibody that targets the alpha-chain of the IL-2 receptor. ...Certain aspects of the immunomodulatory mod
Multiple sclerosis: pathophysiology revisited.
Sorensen PS. Sorensen PS. Lancet Neurol. 2005 Jan;4(1):9-10. doi: 10.1016/S1474-4422(04)00948-2. Lancet Neurol. 2005. PMID: 15620850 Review. No abstract available.
Renal transplantation in adolescents.
Smith JM, McDonald RA. Smith JM, et al. Adolesc Med Clin. 2005 Feb;16(1):201-14. doi: 10.1016/j.admecli.2004.09.003. Adolesc Med Clin. 2005. PMID: 15844392 Review.
1,173 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page